UBS Group Analysts Give EXACT Sciences (EXAS) a $100.00 Price Target

UBS Group set a $100.00 price objective on EXACT Sciences (NASDAQ:EXAS) in a research report sent to investors on Tuesday morning, www.tipranks.com reports. The brokerage currently has a buy rating on the medical research company’s stock.

Several other research analysts have also recently issued reports on the stock. Cowen lifted their target price on shares of EXACT Sciences from $65.00 to $100.00 and gave the stock an outperform rating in a report on Wednesday, September 5th. Bank of America lifted their target price on shares of EXACT Sciences from $68.00 to $92.00 and gave the stock a buy rating in a report on Thursday, September 6th. BidaskClub lowered shares of EXACT Sciences from a buy rating to a hold rating in a research note on Friday, September 14th. Robert W. Baird lifted their price target on shares of EXACT Sciences from $74.00 to $85.00 and gave the stock an outperform rating in a research note on Tuesday, September 11th. Finally, Canaccord Genuity lifted their price target on shares of EXACT Sciences from $72.00 to $87.00 and gave the stock a buy rating in a research note on Wednesday, September 12th. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $84.08.

EXACT Sciences stock traded up $0.78 during trading hours on Tuesday, hitting $74.09. The stock had a trading volume of 61,746 shares, compared to its average volume of 1,960,067. The company has a debt-to-equity ratio of 0.87, a quick ratio of 15.37 and a current ratio of 15.79. The stock has a market capitalization of $7.91 billion, a PE ratio of -75.07 and a beta of 0.98. EXACT Sciences has a 12-month low of $37.36 and a 12-month high of $81.22.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. The business had revenue of $118.29 million during the quarter, compared to analysts’ expectations of $109.33 million. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.69%. The business’s revenue for the quarter was up 63.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.23) earnings per share. As a group, equities research analysts forecast that EXACT Sciences will post -1.45 EPS for the current fiscal year.

In related news, insider D Scott Coward sold 2,190 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $79.51, for a total transaction of $174,126.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Graham Peter Lidgard sold 58,000 shares of the business’s stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $69.36, for a total transaction of $4,022,880.00. Following the sale, the insider now owns 204,684 shares of the company’s stock, valued at $14,196,882.24. The disclosure for this sale can be found here. Insiders sold 62,658 shares of company stock valued at $4,381,737 over the last quarter. Company insiders own 3.20% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Asymmetry Capital Management L.P. grew its position in EXACT Sciences by 229.2% during the second quarter. Asymmetry Capital Management L.P. now owns 84,937 shares of the medical research company’s stock valued at $5,078,000 after buying an additional 59,134 shares during the period. Private Wealth Partners LLC grew its position in EXACT Sciences by 16.7% during the second quarter. Private Wealth Partners LLC now owns 70,000 shares of the medical research company’s stock valued at $4,185,000 after buying an additional 10,000 shares during the period. Swiss National Bank grew its position in EXACT Sciences by 1.4% during the second quarter. Swiss National Bank now owns 210,619 shares of the medical research company’s stock valued at $12,593,000 after buying an additional 3,000 shares during the period. Sit Investment Associates Inc. grew its position in EXACT Sciences by 24.3% during the second quarter. Sit Investment Associates Inc. now owns 33,300 shares of the medical research company’s stock valued at $1,991,000 after buying an additional 6,500 shares during the period. Finally, Legal & General Group Plc grew its position in EXACT Sciences by 10.4% during the second quarter. Legal & General Group Plc now owns 56,154 shares of the medical research company’s stock valued at $3,358,000 after buying an additional 5,312 shares during the period. Institutional investors own 86.52% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: What is the NASDAQ Stock Market?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply